Hitting the sweet spot: optimal use of corticosteroids for immune checkpoint inhibitor side-effects

Effect of corticosteroid dosing on outcomes in high‐grade immune checkpoint inhibitor hepatitis

(2021) Michael Li et al.   HEPATOLOGY

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

(2020) Alexander M. M. Eggermont et al.   JAMA Oncology

Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis

(2020) Xiaoxiang Zhou et al.   BMC Medicine

Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors

(2020) Nicole A. Romanski et al.   EUROPEAN JOURNAL OF CANCER

Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma

(2020) David M Favara et al.   ESMO Open

A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors

(2019) Patrick Arnaud-Coffin et al.   INTERNATIONAL JOURNAL OF CANCER

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

(2017) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY